| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HUP.1096 |
| P698 | PubMed publication ID | 20196183 |
| P2093 | author name string | Alexander Luborzewski | |
| Ion Anghelescu | |||
| Arnim Quante | |||
| Nicole Schommer | |||
| Jens Langosch | |||
| Juergen Wolf | |||
| Christoph Born | |||
| Sara Zeugmann | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| An Inventory for Measuring Depression | Q26778503 | ||
| Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression | Q28247703 | ||
| A rating scale for drug-induced akathisia | Q28258433 | ||
| Effectiveness of adjunctive antidepressant treatment for bipolar depression | Q28295408 | ||
| Self-Reported History of Manic/Hypomanic Switch Associated With Antidepressant Use | Q29391926 | ||
| A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity | Q29547290 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| A rating scale for mania: reliability, validity and sensitivity | Q29619299 | ||
| Historical perspectives and natural history of bipolar disorder | Q33920209 | ||
| Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? | Q33942947 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. | Q34004814 | ||
| Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | Q34275783 | ||
| Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. | Q35631515 | ||
| Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis | Q36433993 | ||
| Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia | Q36711811 | ||
| Augmentation of antidepressants with atypical antipsychotics: a review of the current literature | Q37062820 | ||
| Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review | Q37111491 | ||
| Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial | Q42609214 | ||
| A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression | Q42645277 | ||
| A novel augmentation strategy for treating resistant major depression | Q43514882 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 | ||
| A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 | ||
| Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies | Q46801835 | ||
| Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists | Q46832547 | ||
| Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 | ||
| Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers | Q46921505 | ||
| Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. | Q48765516 | ||
| Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. | Q50656709 | ||
| Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. | Q51900824 | ||
| Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. | Q52900826 | ||
| Mortality in affective disorder | Q72152805 | ||
| The treatment of bipolar depression | Q73617031 | ||
| Antidepressant-associated switches from depression to mania in severe bipolar disorder | Q80189622 | ||
| Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study | Q80207025 | ||
| Factors that affect adherence to bipolar disorder treatments: a stated-preference approach | Q80362225 | ||
| Aripiprazole | Q94460642 | ||
| P433 | issue | 2 | |
| P921 | main subject | placebo | Q269829 |
| bipolar depression | Q56014658 | ||
| P304 | page(s) | 126-132 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Human Psychopharmacology | Q15751477 |
| P1476 | title | Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study | |
| P478 | volume | 25 |
| Q37827220 | A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder |
| Q34502727 | Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms |
| Q37831357 | Aripiprazole for the treatment of bipolar disorder: a review of current evidence |
| Q37827219 | Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness |
| Q22241210 | Bipolar Disorder: An Update |
| Q44142664 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. |
| Q24202141 | Citalopram versus other anti-depressive agents for depression |
| Q34722076 | Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q38259793 | Evaluating aripiprazole as a potential bipolar disorder therapy for adults |
| Q35142737 | Korean Medication Algorithm Project for Bipolar Disorder: third revision |
| Q94569502 | Stabilization Beyond Mood: Stabilizing Patients With Bipolar Disorder in the Various Phases of Life |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q26748677 | The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review |
| Q90151479 | Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder |
| Q83164795 | [Second generation antipsychotics in bipolar depression: a new therapeutic option?] |
Search more.